Scinai Immunotherapeutics... (SCNI)
Company Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Country | IL |
| IPO Date | May 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Amir Reichman M.B.A., M.Sc. |
Contact Details
Address: Jerusalem BioPark Building Jerusalem, IL | |
| Website | https://www.scinai.com |
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| CUSIP Number | 09073Q204 |
| ISIN Number | US09073Q2049 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer & Director |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Alona Tal | Head of Business Administration |
| Dr. Naama Adi Hen | Head of Quality Asurance |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Merav Kamensky | Head of Quality Control |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 05, 2025 | 424B3 | Filing |
| Jun 05, 2025 | 6-K | Filing |
| Jun 02, 2025 | 6-K | Filing |
| May 12, 2025 | POS AM | Filing |
| May 07, 2025 | 20-F | Filing |
| Apr 29, 2025 | NT 20-F | Filing |
| Mar 27, 2025 | 6-K | Filing |
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 24, 2025 | 6-K | Filing |
| Mar 13, 2025 | 424B3 | Filing |